Journal of Clinical Oncology, Vol 22, No 11 (June 1), 2004: pp. 2108-2121
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.02.106
Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer
Christos N. Papandreou,
Danai D. Daliani,
Darrell Nix,
Hong Yang,
Timothy Madden,
Xuemei Wang,
Christine S. Pien,
Randall E. Millikan,
Shi-Ming Tu,
Lance Pagliaro,
Jeri Kim,
Julian Adams,
Peter Elliott,
Dixie Esseltine,
Alexandria Petrusich,
Pauline Dieringer,
Cherie Perez,
Christopher J. Logothetis
From The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Millennium Pharmaceuticals, Inc, Cambridge, MA.
Address reprint requests to Christopher J. Logothetis, MD, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 0427, Houston, TX 77030; e-mail: clogothe{at}mdanderson.org
PURPOSE: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa).
PATIENTS AND METHODS: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.0 mg/m2/dose, utilizing a careful escalation scheme with a continuous reassessment method. Pharmacokinetic and pharmacodynamic studies were performed in 24 patients (at 1.45 to 2.0 mg/m2).
RESULTS: A dose-related 20S PI was seen, with dose-limiting toxicity at 2.0 mg/m2 (diarrhea, hypotension) occurring at an average 1-hour post-dose of  75% 20S PI. Other side effects were fatigue, hypertension, constipation, nausea, and vomiting. No relationship was seen between body-surface area and bortezomib clearance over the narrow dose range tested. There was evidence of biologic activity (decline in serum prostate-specific antigen and interleukin-6 levels) at 50% 20S PI. Two patients with AIPCa had prostate-specific antigen response and two patients had partial response in lymph nodes.
CONCLUSION: The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m2. Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib. This agent should be further explored with chemotherapy agents in advanced prostate cancer.
Supported in part by CaPCURE and Millennium Pharmaceuticals Inc.
Presented in part at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12–15, 2001.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. de Vos, A. Goy, S. R. Dakhil, M. N. Saleh, P. McLaughlin, R. Belt, C. R. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, et al.
Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma
J. Clin. Oncol.,
October 20, 2009;
27(30):
5023 - 5030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Parlati, S. J. Lee, M. Aujay, E. Suzuki, K. Levitsky, J. B. Lorens, D. R. Micklem, P. Ruurs, C. Sylvain, Y. Lu, et al.
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Blood,
October 15, 2009;
114(16):
3439 - 3447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kloss, S. Meiners, A. Ludwig, and B. Dahlmann
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors
Cardiovasc Res,
July 31, 2009;
(2009)
cvp217v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Shah, D. J. Kuhn, and R. Z. Orlowski
Bortezomib and EGCG: no green tea for you?
Blood,
June 4, 2009;
113(23):
5695 - 5696.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M D'Antonio, D. J Vander Griend, and J. T Isaacs
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
Endocr. Relat. Cancer,
June 1, 2009;
16(2):
325 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ceresa, E. Giovannetti, J. Voortman, A. C. Laan, R. Honeywell, G. Giaccone, and G. J. Peters
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1026 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Schewe and J. A. Aguirre-Ghiso
Inhibition of eIF2{alpha} Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy
Cancer Res.,
February 15, 2009;
69(4):
1545 - 1552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Hill, S. Martin, J. L. Armstrong, R. Flockhart, J. J. Tonison, D. G. Simpson, M. A. Birch-Machin, C. P.F. Redfern, and P. E. Lovat
Combining the Endoplasmic Reticulum Stress-Inducing Agents Bortezomib and Fenretinide as a Novel Therapeutic Strategy for Metastatic Melanoma
Clin. Cancer Res.,
February 15, 2009;
15(4):
1192 - 1198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Gomes, G. W. Young, Y. Wang, C. Zong, M. Eghbali, O. Drews, H. Lu, E. Stefani, and P. Ping
Contrasting Proteome Biology and Functional Heterogeneity of the 20 S Proteasome Complexes in Mammalian Tissues
Mol. Cell. Proteomics,
February 1, 2009;
8(2):
302 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Ann. Onc.,
December 1, 2008;
19(12):
2079 - 2083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ayala, J. Yan, R. Li, Y. Ding, T. C. Thompson, M. P. Mims, T. G. Hayes, V. MacDonnell, R. G. Lynch, A. Frolov, et al.
Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt
Clin. Cancer Res.,
November 15, 2008;
14(22):
7511 - 7518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma
Mol. Cancer Ther.,
November 1, 2008;
7(11):
3624 - 3631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-F. Chen, P.-Y. Yeh, K.-H. Yeh, Y.-S. Lu, S.-Y. Huang, and A.-L. Cheng
Down-regulation of Phospho-Akt Is a Major Molecular Determinant of Bortezomib-Induced Apoptosis in Hepatocellular Carcinoma Cells
Cancer Res.,
August 15, 2008;
68(16):
6698 - 6707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Sloss, F. Wang, R. Liu, L. Xia, M. Houston, D. Ljungman, M. A. Palladino, and J. C. Cusack Jr.
Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells
Clin. Cancer Res.,
August 15, 2008;
14(16):
5116 - 5123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Utecht and J. Kolesar
Bortezomib: A novel chemotherapeutic agent for hematologic malignancies
Am. J. Health Syst. Pharm.,
July 1, 2008;
65(13):
1221 - 1231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Allen, K. Saigal, L. Nottingham, P. Arun, Z. Chen, and C. Van Waes
Bortezomib-Induced Apoptosis with Limited Clinical Response Is Accompanied by Inhibition of Canonical but not Alternative Nuclear Factor-{kappa}B Subunits in Head and Neck Cancer
Clin. Cancer Res.,
July 1, 2008;
14(13):
4175 - 4185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz
Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study
J. Clin. Oncol.,
May 10, 2008;
26(14):
2320 - 2326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Schmid, D. Kuhnhardt, P. Kiewe, S. Lehenbauer-Dehm, W. Schippinger, R. Greil, W. Lange, J. Preiss, N. Niederle, P. Brossart, et al.
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
Ann. Onc.,
May 1, 2008;
19(5):
871 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski and D. J. Kuhn
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Clin. Cancer Res.,
March 15, 2008;
14(6):
1649 - 1657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res.,
March 1, 2008;
14(5):
1446 - 1454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood,
February 1, 2008;
111(3):
1309 - 1317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Colado, S. Alvarez-Fernandez, P. Maiso, J. Martin-Sanchez, M. B. Vidriales, M. Garayoa, E. M. Ocio, J. C. Montero, A. Pandiella, and J. F. San Miguel
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
Haematologica,
January 1, 2008;
93(1):
57 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kuhn, Q. Chen, P. M. Voorhees, J. S. Strader, K. D. Shenk, C. M. Sun, S. D. Demo, M. K. Bennett, F. W. B. van Leeuwen, A. A. Chanan-Khan, et al.
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
Blood,
November 1, 2007;
110(9):
3281 - 3290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Poulaki, C. S. Mitsiades, V. Kotoula, J. Negri, D. McMillin, J. W. Miller, and N. Mitsiades
The Proteasome Inhibitor Bortezomib Induces Apoptosis in Human Retinoblastoma Cell Lines In Vitro
Invest. Ophthalmol. Vis. Sci.,
October 1, 2007;
48(10):
4706 - 4719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Demo, C. J. Kirk, M. A. Aujay, T. J. Buchholz, M. Dajee, M. N. Ho, J. Jiang, G. J. Laidig, E. R. Lewis, F. Parlati, et al.
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Cancer Res.,
July 1, 2007;
67(13):
6383 - 6391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chabner
Phase II Cancer Trials: Out of Control?
Clin. Cancer Res.,
April 15, 2007;
13(8):
2307 - 2308.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Horton, D. Pati, S. E. Plon, P. A. Thompson, L. R. Bomgaars, P. C. Adamson, A. M. Ingle, J. Wright, A. H. Brockman, M. Paton, et al.
A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study
Clin. Cancer Res.,
March 1, 2007;
13(5):
1516 - 1522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Van Waes
Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer
Clin. Cancer Res.,
February 15, 2007;
13(4):
1076 - 1082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth
Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Clin. Cancer Res.,
February 15, 2007;
13(4):
1208 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Markasz, G. Stuber, B. Vanherberghen, E. Flaberg, E. Olah, E. Carbone, S. Eksborg, E. Klein, H. Skribek, and L. Szekely
Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells
Mol. Cancer Ther.,
February 1, 2007;
6(2):
644 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al.
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
November 1, 2006;
24(31):
5025 - 5033.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K. B. Ain, and N. Mitsiades
Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro
J. Clin. Endocrinol. Metab.,
October 1, 2006;
91(10):
4013 - 4021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campas, L. Dang, et al.
Interleukin 6, a Nuclear Factor-{kappa}B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-{kappa}B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5578 - 5586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Canfield, K. Zhu, S. A. Williams, and D. J. McConkey
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Mol. Cancer Ther.,
August 1, 2006;
5(8):
2043 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nencioni, K. Schwarzenberg, K. M. Brauer, S. M. Schmidt, A. Ballestrero, F. Grunebach, and P. Brossart
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Blood,
July 15, 2006;
108(2):
551 - 558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, H. Briemberg, S. Jagannath, P. Y. Wen, B. Barlogie, J. Berenson, S. Singhal, D. S. Siegel, D. Irwin, M. Schuster, et al.
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
J. Clin. Oncol.,
July 1, 2006;
24(19):
3113 - 3120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Yang, A. M. Gonzalez-Angulo, J. M. Reuben, D. J. Booser, L. Pusztai, S. Krishnamurthy, D. Esseltine, J. Stec, K. R. Broglio, R. Islam, et al.
Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
Ann. Onc.,
May 1, 2006;
17(5):
813 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sors, F. Jean-Louis, C. Pellet, L. Laroche, L. Dubertret, G. Courtois, H. Bachelez, and L. Michel
Down-regulating constitutive activation of the NF-{kappa}B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis
Blood,
March 15, 2006;
107(6):
2354 - 2363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Codony-Servat, M. A. Tapia, M. Bosch, C. Oliva, J. Domingo-Domenech, B. Mellado, M. Rolfe, J. S. Ross, P. Gascon, A. Rovira, et al.
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Mol. Cancer Ther.,
March 1, 2006;
5(3):
665 - 675.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos
Pulmonary toxicity from novel antineoplastic agents
Ann. Onc.,
March 1, 2006;
17(3):
372 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. Messersmith, S. D. Baker, L. Lassiter, R. A. Sullivan, K. Dinh, V. I. Almuete, J. J. Wright, R. C. Donehower, M. A. Carducci, and D. K. Armstrong
Phase I Trial of Bortezomib in Combination with Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
February 15, 2006;
12(4):
1270 - 1275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Perez-Galan, G. Roue, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
Blood,
January 1, 2006;
107(1):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Huang, S.-L. Pan, J.-H. Guh, Y.-L. Chang, F.-Y. Lee, S.-C. Kuo, and C.-M. Teng
YC-1 suppresses constitutive nuclear factor-{kappa}B activation and induces apoptosis in human prostate cancer cells
Mol. Cancer Ther.,
October 1, 2005;
4(10):
1628 - 1635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Alberts, N. R. Foster, R. F. Morton, J. Kugler, P. Schaefer, M. Wiesenfeld, T. R. Fitch, P. Steen, G. P. Kim, and S. Gill
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
Ann. Onc.,
October 1, 2005;
16(10):
1654 - 1661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Aghajanian, D.S. Dizon, P. Sabbatini, J.J. Raizer, J. Dupont, and D.R. Spriggs
Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer
J. Clin. Oncol.,
September 1, 2005;
23(25):
5943 - 5949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.L. Hamilton, J.P. Eder, A.C. Pavlick, J.W. Clark, L. Liebes, R. Garcia-Carbonero, A. Chachoua, D.P. Ryan, V. Soma, K. Farrell, et al.
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
J. Clin. Oncol.,
September 1, 2005;
23(25):
6107 - 6116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Mackay, D. Hedley, P. Major, C. Townsley, M. Mackenzie, M. Vincent, P. Degendorfer, M.-S. Tsao, T. Nicklee, D. Birle, et al.
A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res.,
August 1, 2005;
11(15):
5526 - 5533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nencioni, L. Wille, G. Dal Bello, D. Boy, G. Cirmena, S. Wesselborg, C. Belka, P. Brossart, F. Patrone, and A. Ballestrero
Cooperative Cytotoxicity of Proteasome Inhibitors and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Chemoresistant Bcl-2-Overexpressing Cells
Clin. Cancer Res.,
June 1, 2005;
11(11):
4259 - 4265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Dy, J. P. Thomas, G. Wilding, L. Bruzek, S. Mandrekar, C. Erlichman, D. Alberti, K. Binger, H. C. Pitot, S. R. Alberts, et al.
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Clin. Cancer Res.,
May 1, 2005;
11(9):
3410 - 3416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nencioni, F. Hua, C. P. Dillon, R. Yokoo, C. Scheiermann, M. H. Cardone, E. Barbieri, I. Rocco, A. Garuti, S. Wesselborg, et al.
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis
Blood,
April 15, 2005;
105(8):
3255 - 3262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goy, A. Younes, P. McLaughlin, B. Pro, J. E. Romaguera, F. Hagemeister, L. Fayad, N. H. Dang, F. Samaniego, M. Wang, et al.
Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
February 1, 2005;
23(4):
667 - 675.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Shah, D. Young, H. L. Kindler, I. Webb, B. Kleiber, J. Wright, and M. Grever
Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Clin. Cancer Res.,
September 15, 2004;
10(18):
6111 - 6118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Papandreou and C. J. Logothetis
Bortezomib as a Potential Treatment for Prostate Cancer
Cancer Res.,
August 1, 2004;
64(15):
5036 - 5043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
